Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in various types of cancer. However, few anti-lymphangiogenic drugs have been approved for clinical use to date. Therefore, new therapies to block lymphangiogenesis are urgently required. Methods: Immunohistochemis...

Full description

Bibliographic Details
Main Authors: Tingting Qin, Zhujun Liu, Jing Wang, Junling Xia, Shaochuan Liu, Yanan Jia, Hailin Liu, Kai Li
Format: Article
Language:English
Published: China Anti-Cancer Association 2020-08-01
Series:Cancer Biology & Medicine
Subjects:
anlotinib
vegfr-3 dephosphorylation
lymphangiogenesis
lymph node metastasis
lung adenocarcinoma
Online Access:http://www.cancerbiomed.org/index.php/cocr/article/view/1681

Internet

http://www.cancerbiomed.org/index.php/cocr/article/view/1681

Similar Items